Sue Ashton

Barriers to evidence‐based practice in primary care

Hugh McKenna, Sue Ashton, Sinead Keeney · Journal of Advanced Nursing · 2004 · 195 citations

Nursing, Health Systems, Evidence-based Practice +11

Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models.

David C. Blakey, F. Russell Westwood, Mike Walker et al. · PubMed · 2002 · 176 citations

Medicine, Oncology, Pharmacology +16

Assessing the Activity of Cediranib, a VEGFR-2/3 Tyrosine Kinase Inhibitor, against VEGFR-1 and Members of the Structurally Related PDGFR Family

Sandra R. Brave, Kirsty Ratcliffe, Zena Wilson et al. · Molecular Cancer Therapeutics · 2011 · 88 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +15

Discovery of AZD2932, a new Quinazoline Ether Inhibitor with high affinity for VEGFR-2 and PDGFR tyrosine kinases

Patrick A. Plé, Frédéric Jung, Sue Ashton et al. · Bioorganic & Medicinal Chemistry Letters · 2011 · 48 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +13

Liposomal encapsulation enhances the antitumour efficacy of the vascular disrupting agent ZD6126 in murine B16.F10 melanoma

Marcel H.A.M. Fens, Kathryn J. Hill, Jean‐Pierre J. Issa et al. · British Journal of Cancer · 2008 · 31 citations · Full text

Pharmacy, Oncology, Pharmacology +17